- Home
- AGMH vs EVAX Comparison
AGMH vs EVAX Comparison
Compare AGMH & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- EVAX
- Stock Information
- Founded
- AGMH 2015
- EVAX 2008
- Country
- AGMH Hong Kong
- EVAX Denmark
- Employees
- AGMH N/A
- EVAX N/A
- Industry
- AGMH EDP Services
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AGMH Technology
- EVAX Health Care
- Exchange
- AGMH Nasdaq
- EVAX Nasdaq
- Market Cap
- AGMH 1.8M
- EVAX 16.3M
- IPO Year
- AGMH 2018
- EVAX 2021
- Fundamental
- Price
- AGMH $0.05
- EVAX $1.69
- Analyst Decision
- AGMH
- EVAX Strong Buy
- Analyst Count
- AGMH 0
- EVAX 2
- Target Price
- AGMH N/A
- EVAX $10.00
- AVG Volume (30 Days)
- AGMH 73.1M
- EVAX 65.8K
- Earning Date
- AGMH 04-15-2025
- EVAX 05-27-2025
- Dividend Yield
- AGMH N/A
- EVAX N/A
- EPS Growth
- AGMH N/A
- EVAX N/A
- EPS
- AGMH N/A
- EVAX N/A
- Revenue
- AGMH $64,998,081.00
- EVAX $3,344,000.00
- Revenue This Year
- AGMH N/A
- EVAX $102.45
- Revenue Next Year
- AGMH N/A
- EVAX $200.44
- P/E Ratio
- AGMH N/A
- EVAX N/A
- Revenue Growth
- AGMH N/A
- EVAX 4480.82
- 52 Week Low
- AGMH $0.04
- EVAX $1.61
- 52 Week High
- AGMH $2.19
- EVAX $22.05
- Technical
- Relative Strength Index (RSI)
- AGMH 24.28
- EVAX 36.47
- Support Level
- AGMH $0.04
- EVAX $1.67
- Resistance Level
- AGMH $0.09
- EVAX $1.97
- Average True Range (ATR)
- AGMH 0.01
- EVAX 0.12
- MACD
- AGMH 0.03
- EVAX 0.04
- Stochastic Oscillator
- AGMH 8.39
- EVAX 22.22
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.